Imagine taking a pill that helps your heart and protects your kidneys at the same time. That is what researchers are now exploring with a traditional Chinese medicine called Shexiang Baoxin pill, also known by the brand name MUSKARDIA.
This is not a new drug. It has been used for years in China to treat heart disease. But a recent study suggests it may do something extra. It may help people whose kidneys are not working as well as they should.
Here is why that matters for millions of people.
Heart disease and kidney disease often go hand in hand. About half of people with heart disease also have some degree of kidney trouble. When the kidneys slow down, the heart has to work harder. This creates a dangerous cycle.
Doctors have few good options for these patients. Many heart medications can be hard on the kidneys. Some blood thinners and blood pressure drugs need careful dose adjustments. Patients and doctors are often stuck between treating one organ and hurting the other.
But here is the twist. This pill may help both at the same time.
The Shexiang Baoxin pill comes from a blend of natural ingredients. Think of it like a team of workers inside your body. Some ingredients help blood vessels relax. Others reduce inflammation. A few may even help the body use oxygen more efficiently.
The key ingredient is musk, which comes from a gland of the musk deer. But the formula also includes other herbs. Together, they work on multiple targets at once.
Think of it this way. Your blood vessels are like highways. When they get narrow or clogged, traffic slows down. The heart has to pump harder. The kidneys do not get enough blood flow. This pill may help keep those highways open and clear.
The study looked at 1,354 people with stable coronary artery disease and reduced kidney function. Reduced kidney function means their estimated glomerular filtration rate, or eGFR, was below 90. This is a common measure of how well the kidneys filter waste.
Patients were randomly assigned to take either the Shexiang Baoxin pill or a placebo. They took it for a long time. The study followed them for over a year.
What did the researchers find?
The numbers showed a clear trend. People taking the pill had fewer heart attacks, strokes, and hospitalizations for chest pain or heart failure. The risk of these events dropped by about 29 percent for the main measure the researchers tracked.
But there is a catch.
The results did not reach statistical significance for the primary endpoint. That is a fancy way of saying the numbers looked promising but did not quite meet the strict bar scientists use to be sure the effect is real.
However, when the researchers adjusted for other factors like age, sex, and other health conditions, the benefit became clearer. After 14 months, the pill showed a significant improvement in preventing a combination of serious events including death, heart attack, stroke, and hospitalizations.
The safety news was also good. The pill did not cause any major side effects. Liver and kidney function stayed stable. This matters because many heart drugs can harm the kidneys over time.
Dr. Wei Chen, a cardiologist not involved in the study, told ClinicalPulse that the findings are encouraging but preliminary. "We need larger trials that focus specifically on patients with kidney disease," he said. "But the safety profile is reassuring."
What does this mean for you?
If you have stable heart disease and your doctor has mentioned your kidneys are not working at full speed, this is worth a conversation. But do not expect to get this pill at your local pharmacy tomorrow.
The study has limits. It was a subgroup analysis, meaning researchers looked back at data from a larger trial. This type of analysis can suggest benefits but cannot prove them. The number of patients was also relatively small for drawing firm conclusions.
Also, this pill is not approved by the FDA for use in the United States. It is available in China and some other Asian countries as a prescription medicine.
What happens next?
Researchers plan to design a larger trial focused specifically on patients with both heart and kidney disease. That trial will need to confirm these results before doctors can feel confident prescribing the pill for this purpose.
Research takes time. Good research takes even longer. But for the millions of people living with both heart and kidney problems, this study offers a glimmer of hope. Sometimes the next big advance comes not from a brand new molecule, but from looking at an old remedy with fresh eyes.
